atai Life Sciences (ATAI) Misses Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
atai Life Sciences N.V (ATAI) PT Lowered to $5 at Jefferies
August 13, 2024 4:04 PM EDTJefferies analyst Andrew Tsai lowered the price target on atai Life Sciences N.V (NASDAQ: ATAI) to $5.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "ATAI's pipeline of psychedelics (and non-psychedelics) has pot'l to safely, profoundly, and durably treat tough $1B+... More
